qPCR
The advances in treatments have made it possible to include new genetic diseases to the panel of diseases eligible for neonatal screening. These diseases can be detected by finding the site of the specific DNA mutation.
LaCAR is developing its range and expanding its technology portfolio by adding qPCR to its already reputed enzyme range. The DNA analysis range includes kits for first-line neonatal screening suitable for the use of dried blood samples.
The NEONATAL SCID&SMA Screening qPCR Flex kit is an assay intended for the semi-quantitative determination of TREC, aiding in the screening of newborns for Severe Combined Immunodeficiency (SCID), and for the qualitative detection of the SMN1 gene (Exon 7), aiding in the screening of newborns for Spinal Muscular Atrophy (SMA).
Fluorometry
Our fluorometric screening line combines immunoassays and enzymatic assays to cover the core metabolic and endocrine panel: PKU, congenital hypothyroidism, CF (IRT), CAH, galactosemia, MSUD, biotinidase and G6PD deficiency.
Mass
spectrometry Our mass spectrometry line resolves clinically significant hemoglobin variants with MS/MS sensitivity. Sample multiplexing keeps throughput high for large-scale programmes.
spectrometry Our mass spectrometry line resolves clinically significant hemoglobin variants with MS/MS sensitivity. Sample multiplexing keeps throughput high for large-scale programmes.
Digital Microfluidics
Our digital microfluidics (DMF) line measures enzyme activity to screen for lysosomal storage diseases - multiplexed screening from very small volumes on a compact and user-friendly platform.
You have a question regarding our products ? You want to know more about our method ?
Find out about our other expertises
Genetic testing
CE Kits
Pharmacogenetics
Genetic testing
CE Kits
Genetic predispositions and disorders
